Ipsen launch's Dysport in USA, updates on taspoglutide

French specialty pharmaceutical group says that its drug Dysport (abobotulinumtoxinA for Injection) is now available in the USA for the treatment of cervical dystonia in adults and announced positive findings with its diabetes drug taspoglutide.

Used in patient care in the UK since 1991, Dysport has marketing authorizations in 75 countries (as of December 31, 2008) for multiple therapeutic uses.

Dysport was approved by the US Food and Drug Administration on April 29 for two separate indications, the treatment of cervical dystonia to reduce the severity of abnormal head position and neck pain in both toxin-naïve and previously treated patients, and the temporary improvement in the appearance of moderate to severe glabellar lines in adults younger than 65 years of age. Ipsen will market the product in the USA for the therapeutic indication of cervical dystonia, while Medicis already markets it for the aesthetic indication.

Roche tests of taspoglutide meet primary endpoints, drug beats Byetta